tapebrief

HUM · Q2 2025 Earnings

Cautious

Humana

Reported July 30, 2025

30-second summary

Humana posted Q2 revenue of $32.4B (+9.6% YoY) and adjusted EPS of $6.27, and raised FY2025 guidance to "at least $128B" revenue and "approximately $17.00" adjusted EPS. The MA membership decline guide narrowed to "up to 500,000" (better than the prior "up to 550,000" framing management referenced in Q&A), and CenterWell pharmacy is driving the upside via GLP-1 distribution partnerships and limited-distribution drug wins. The cautious posture is warranted: insurance benefit ratio guidance was affirmed (not lowered) at 90.1–90.5%, STARS Plan Preview 1 data is still pending, and management declined to discuss RAD-V audit exposure citing active litigation.

Headline numbers

EPS

Q2 FY2025

$6.27

Revenue

Q2 FY2025

$32.39B

+9.6% YoY

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$32.39B+9.6%
EPS$6.27—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Insurance Segment$31.094B+9.0%
CenterWell Segment$5.537B+11.9%
Individual Medicare Advantage$22.764B+2.5%
Group Medicare Advantage$2.26B+16.6%
Medicare stand-alone PDP$1.721B+98.6%
State-based contracts and other$3.46B+37.0%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Insurance Segment Benefit Ratio89.9%
Insurance Segment Operating Cost Ratio8.3%
Consolidated Benefit Ratio89.7%
Consolidated Operating Cost Ratio11.0%
Individual Medicare Advantage Membership5,229.3 thousand members
Total Medicare Membership8,226.4 thousand members
Days in Claims Payable36.5 days
Debt-to-Total Capitalization40.7%

Management tone

Transcript coverage was limited to the prepared-remarks opening and Q&A; full prepared-remarks commentary was not available, so a multi-quarter tone arc cannot be constructed for this first-coverage brief. The Q&A posture is documented below.

Management's Q&A posture was confident but deliberately bounded. On STARS — the single largest swing factor for 2027 earnings — they entered a self-described quiet period until the October CMS release, declining to characterize Plan Preview 1 trajectory beyond saying underlying metrics have "improved since September baseline." On RAD-V audit exposure, they declined to engage at all, citing active litigation. The willingness to flag both as no-go zones, rather than offer reassuring color, is the most telling signal in the call: management is protecting credibility on the two topics where being wrong would be most expensive.

Where they were willing to elaborate — CenterWell pharmacy, bounce-back membership, Medicaid LTSS positioning — the framing was specific and operational rather than promotional. The MA bounce-back discussion in particular leaned on better year-one unit economics ("known members with improved clinical care") rather than just headline numbers, which is the more durable argument.

Q&A highlights

Ann Hines · Mizuho

Clarification on what cost trends are better than expectations, and how Medicaid is performing given peer challenges in the acute business.

Revenue is better than expected driven by CenterWell pharmacy higher patient growth and individual MA membership growth (550k decline vs 600k expected). Medicaid trending in line with expectations. Management emphasized Medicaid differentiation through LTSS population focus, state selection, and value-based care network structure, mitigating impacts of macro trends.

MA membership decline guidance improved to 500k from 550kMedicaid footprint expanded to 10 active states with 3 more pendingMedicaid heavily oriented toward LTSS population vs. traditional MedicaidPart D trending in line with expectations with low double-digit RX trends

Justin Lake · Wolfe Research

Request for early color on STARS performance given Plan Preview 1 data availability and underlying metric improvement trajectory ahead of quiet period.

Management declined to disclose STARS performance details, noting Plan Preview 1 data has not been received and entering quiet period until October CMS release. Acknowledged operational progress made since late September/early October baseline and expressed confidence in underlying metric improvements, but emphasized uncertainty on industry-wide improvement and cut point positioning.

Plan Preview 1 data not yet availableEntering quiet period on BY27 STARS discussion until October CMS releaseUnderlying metric performance has improved since September baselineConfidence in BY28 trajectory despite benefit cuts taken in 24-25

Erin Wright · Morgan Stanley

Details on specialty pharmacy outperformance drivers and Part D dynamics relative to IRA expectations.

Specialty pharmacy outperformance driven by: (1) strategic partnerships with pharma companies (Novo, Roe, Weight Watchers for GLP-1 direct-to-consumer), (2) winning access to limited distribution drugs previously unavailable, (3) broader industry specialty outperformance. Part D member mix and RX trends tracking in line with expectations with no unexpected behavioral changes.

New direct-to-consumer partnerships with Novo, Roe, and Weight Watchers for GLP-1 productsWon new access to multiple limited distribution drugs through pharma partnershipsPart D RX trends low double digits in line with expectationsNo unexpected member behavioral changes in Part D

George Hill · Deutsche Bank

Drivers of bounce-back membership returning to Humana and what benefit perspectives are attracting returnees.

Bounce-back membership broad-based across regions with prior membership losses. Members typically return due to surprise with competing plan offerings (unexpected benefits, customer service gaps). Clear benefit communication and Humana's known service reputation drive returns. Bounce-back members have better year-one economics and inform benefit strategy refinements.

Bounce-back membership disproportionately from regions with prior lossesMembers return due to unmet expectations with competitor offeringsBounce-back members have better year-one economics (known members with improved clinical care)Broad-based pattern across regions, no specific concentrated source

Ben Hendricks · RBC Capital Markets

Impact of conservative MA benefit actions in 24-25 vs. peers on member experience ahead of STARS, and offsetting investment measures to maintain STARS targets.

Management acknowledges member abrasion from benefit cuts but monitoring closely via NPS metrics (NPSR/NPST), mock CMS surveys showing no concerning trends. Offsetting actions include: clear member communication, responsive support, Epic MyChart integration with payers, multi-million dollar investments in member experience and care access. Bounce-back membership cited as proof measures working. STARS trajectory remains positive even accounting for benefit cuts.

NPS metrics and mock CMS surveys show no alarming member experience deteriorationEpic MyChart integration first mover in plan-payer visibility for membersMulti-million dollar investments in STARS-related outcomes and member experienceBounce-back membership validates benefit strategy effectiveness

What to watch into next quarter

STARS Plan Preview 1 results post-October CMS release — management exited the call in a quiet period. Watch whether the BY27 STARS percentages enrolled in 4+ star plans rebuild from the current depressed level, which gates 2027 bonus revenue.

Insurance segment benefit ratio trajectory toward the 90.1–90.5% FY guide — Q2 ran at 89.9%, leaving room above. Watch Q3 for whether utilization patterns or seasonal mix push the ratio into the upper half of the guide range or force an Q3 revision.

MA membership decline finalization — guide narrowed to "up to 500,000." Watch whether Q3 disclosure tightens further (suggesting AEP momentum) or widens back out.

CenterWell Pharmacy GLP-1 partnership economics — direct-to-consumer wins with Novo, Ro, and Weight Watchers are driving the upside. Watch whether Q3 segment revenue growth holds the 11.9% rate or accelerates, and whether margin disclosure confirms these are accretive.

RAD-V audit and CMS callback exposure — management declined comment citing litigation. Watch for any 10-Q disclosure update or court docket movement before the Q3 print.

CenterWell Primary Care net patient growth — guide of 50,000–70,000 is the new range. Watch whether Q3 puts management at the top end, which would imply a Q4 raise.

Sources

  1. Humana Q2 2025 detailed press release (8-K Ex. 99.2): https://www.sec.gov/Archives/edgar/data/49071/000004907125000039/hum-2025q28kxex99x2detailed.htm
  2. Q2 2025 earnings call Q&A excerpts (analyst exchanges with Mizuho, Wolfe, Morgan Stanley, Deutsche Bank, RBC)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.